|
Keytruda Clinical Trials
9 actively recruiting trials across 3 locations
▲ +1 trial since August 2026
Also known as: MK-3475, Pembrolizumab, pembrolizumab
Pipeline
Phase 1: 1Phase 2: 4Phase 3: 1Phase 1/2: 3
Top Sponsors
- Strand Therapeutics Inc.2
- University of Leipzig1
- Qilu Pharmaceutical Co., Ltd.1
- Philogen S.p.A.1
- National Cancer Institute (NCI)1
Indications
- Cancer9
- Lung Cancer3
- Advanced Solid Tumor2
- Breast Cancer2
- Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer1
Other5 trials
Scottsdale, Arizona2 trials
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
HonorHealth Research and Innovation Institute
Phase 1/2
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
HonorHealth Research Institute
Phase 1/2
Hartford, Connecticut1 trial
Bethesda, Maryland1 trial
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.